Oridonin from : An Emerging Potential in Cancer Therapy - A Comprehensive Review

Overview

Journal Food Sci Nutr

Specialty Biotechnology

Date 2024 May 10

PMID 38726411

Authors

Muhammad Asif Ali

Noohela Khan

Ahmad Ali

Hira Akram

Noushaba Zafar

Kinza Imran

Tooba Khan

Khushbukhat Khan

Muhammad Armaghan

Marta Palma-Morales

Celia Rodriguez-Perez

Angela Caunii

Monica Butnariu

Solomon Habtemariam

Javad Sharifi-Rad

Affiliations

Soon will be listed here.

Abstract

Cancer incidences are rising each year. In 2020, approximately 20 million new cancer cases and 10 million cancer-related deaths were recorded. The World Health Organization (WHO) predicts that by 2024 the incidence of cancer will increase to 30.2 million individuals annually. Considering the invasive characteristics of its diagnostic procedures and therapeutic methods side effects, scientists are searching for different solutions, including using plant-derived bioactive compounds, that could reduce the probability of cancer occurrence and make its treatment more comfortable. In this regard, oridonin (ORI), an ent-kaurane diterpenoid, naturally found in the leaves of species, has been found to have antitumor, antiangiogenesis, antiasthmatic, antiinflammatory, and apoptosis induction properties. Extensive research has been performed on ORI to find various mechanisms involved in its anticancer activities. This review article provides an overview of ORI's effectiveness on murine and human cancer populations from 1976 to 2022 and provides insight into the future application of ORI in different cancer therapies.

Citing Articles

Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Su Y, Liu L, Lin C, Deng D, Li Y, Huang M Front Pharmacol. 2024; 15:1476739.

PMID: 39691396 PMC: 11649421. DOI: 10.3389/fphar.2024.1476739.

Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.

Aumann W, Kazi R, Harrington A, Wechsler D Oncol Rev. 2024; 18:1427497.

PMID: 39161560 PMC: 11330842. DOI: 10.3389/or.2024.1427497.

Oridonin from : An emerging potential in cancer therapy - A comprehensive review.

Ali M, Khan N, Ali A, Akram H, Zafar N, Imran K Food Sci Nutr. 2024; 12(5):3046-3067.

PMID: 38726411 PMC: 11077219. DOI: 10.1002/fsn3.3986.

References

Yi S, Chen Y, Wen L, Yang L, Cui G . Downregulation of nucleoporin 88 and 214 induced by oridonin may protect OCIM2 acute erythroleukemia cells from apoptosis through regulation of nucleocytoplasmic transport of NF-κB. Int J Mol Med. 2012; 30(4):877-83. DOI: 10.3892/ijmm.2012.1067. View

Xue B, Wang Y, Tang X, Xie P, Wang Y, Luo F . Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J Biomed Nanotechnol. 2012; 8(1):80-9. DOI: 10.1166/jbn.2012.1358. View

Leng X, Huang H, Wang W, Sai N, You L, Yin X . Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin. Evid Based Complement Alternat Med. 2019; 2018:3249023. PMC: 6304552. DOI: 10.1155/2018/3249023. View

Li D, Wu L, Tashiro S, Onodera S, Ikejima T . Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull. 2007; 30(2):254-60. DOI: 10.1248/bpb.30.254. View

Huang H, Weng H, Wang L, Yu C, Huang Q, Zhao P . Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012; 11(5):1155-65. DOI: 10.1158/1535-7163.MCT-12-0066. View

Gui Y, Cheng J, Chen Z . Oridonin improves the therapeutic effect of lentinan on lung cancer. Exp Ther Med. 2021; 22(2):886. PMC: 8237276. DOI: 10.3892/etm.2021.10318. View

Cheng Y, Qiu F, Ye Y, Tashiro S, Onodera S, Ikejima T . Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009; 490(1):70-5. DOI: 10.1016/j.abb.2009.08.011. View

Meade-Tollin L, Wijeratne E, Cooper D, Guild M, Jon E, Fritz A . Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod. 2004; 67(1):2-4. DOI: 10.1021/np0304114. View

Kang N, Cao S, Zhou Y, He H, Tashiro S, Onodera S . Inhibition of caspase-9 by oridonin, a diterpenoid isolated from Rabdosia rubescens, augments apoptosis in human laryngeal cancer cells. Int J Oncol. 2015; 47(6):2045-56. PMC: 4665153. DOI: 10.3892/ijo.2015.3186. View

10.

Zhao J, Zhang M, Chen Y . [Experimental research on the mechanisms of human multiple myeloma LP-1 cell apoptosis induced by oridonin]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013; 32(12):1642-6. View

11.

Chen J, Wang S, Li E, Chen L, Yuan S, Wang R . [Inhibitory effect of Oridonin injection on heterotransplanted gastric adenocarcinoma in nude mice and its mechanism]. Zhonghua Zhong Liu Za Zhi. 2008; 30(2):89-92. View

12.

Xu S, Yao H, Hu M, Li D, Zhu Z, Xie W . 6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. J Nat Prod. 2017; 80(9):2391-2398. DOI: 10.1021/acs.jnatprod.7b00057. View

13.

Zeng R, Chen Y, Zhao S, Cui G . Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol Sin. 2011; 33(1):91-100. PMC: 4010261. DOI: 10.1038/aps.2011.143. View

14.

Hwang T, Chang C . Oridonin enhances cytotoxic activity of natural killer cells against lung cancer. Int Immunopharmacol. 2023; 122:110669. DOI: 10.1016/j.intimp.2023.110669. View

15.

Wang Y, Lv Y, Lu L, Cai L . Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs. 2014; 25(10):1192-200. DOI: 10.1097/CAD.0000000000000154. View

16.

Xu L, Bi Y, Xu Y, Zhang Z, Xu W, Zhang S . Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J Cell Mol Med. 2020; 24(8):4480-4493. PMC: 7176879. DOI: 10.1111/jcmm.15106. View

17.

Li D, Wu L, Tashiro S, Onodera S, Ikejima T . Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res. 2007; 10(1-2):77-87. DOI: 10.1080/10286020701273866. View

18.

Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D . Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces. 2011; 87(2):319-25. DOI: 10.1016/j.colsurfb.2011.05.037. View

19.

Bu H, Shen F, Cui J . The inhibitory effect of oridonin on colon cancer was mediated by deactivation of TGF-β1/Smads-PAI-1 signaling pathway in vitro and vivo. Onco Targets Ther. 2019; 12:7467-7476. PMC: 6752205. DOI: 10.2147/OTT.S220401. View

20.

Li H, Mu J, Sun J, Xu S, Liu W, Xu F . Hydrogen sulfide releasing oridonin derivatives induce apoptosis through extrinsic and intrinsic pathways. Eur J Med Chem. 2019; 187:111978. DOI: 10.1016/j.ejmech.2019.111978. View